Raymond James & Associates Spring Works Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 15,792 shares of SWTX stock, worth $591,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,792
Previous 10,421
51.54%
Holding current value
$591,252
Previous $392,000
28.83%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SWTX
# of Institutions
238Shares Held
69.8MCall Options Held
144KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA6.71MShares$251 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$210 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.84MShares$144 Million4.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.52MShares$132 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$128 Million5.82% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.34B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...